Sartorius Stedim BiotechSRTOY -0.50%82 Interest Coverage is 3.21 as of Mar. 2026, which is 94% below its 10-year median of 56.81. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.93 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 78.85% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Sartorius Stedim Biotech's
Operating Income
for the
three
months ended in Mar. 2026 was $173 Mil. Sartorius Stedim Biotech's Interest Expense for the
three
months ended in Mar. 2026 was $-54 Mil.
Sartorius Stedim Biotech's interest coverage for the quarter that ended in Mar. 2026 was 3.21.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Sartorius Stedim Biotech's Interest Coverage or its related term are showing as below:
SRTOY'
s Interest Coverage Range Over the Past 10 Years
Min: 2.66 Med: 56.81 Max: 84.9
Current: 4.46
SRTOY's Interest Coverage is ranked worse than 78.85% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 15.71
vs SRTOY: 4.46
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Sartorius Stedim Biotech Interest Coverage Related Terms
Sartorius Stedim Biotech Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SRTOY vs ISRG, BDX, MDLN: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (SRTOY) has a Interest Coverage of 3.21 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sartorius Stedim Biotech and its competitors. This is 94% below median its historical median of 56.81. Over the past decade, Sartorius Stedim Biotech's Interest Coverage has ranged from 2.66 to 84.90. According to the industry distribution chart, Sartorius Stedim Biotech ranks #369 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 78.8%.
Is Sartorius Stedim Biotech's Interest Coverage too high?
Sartorius Stedim Biotech's current Interest Coverage of 3.21 is 94% below median its 10-year median of 56.81. Over the past 10 years, this metric has ranged from a low of 2.66 to a high of 84.90. The Medical Devices & Instruments industry median Interest Coverage is 15.71. Sartorius Stedim Biotech's value of 3.21 is 79.6% below this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #369 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Interest Coverage compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #369 out of 468 companies for Interest Coverage. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Interest Coverage is 15.71. Sartorius Stedim Biotech's value of 3.21 is 79.6% below this benchmark. Historically, Sartorius Stedim Biotech's own Interest Coverage has ranged from 2.66 to 84.90 over the past decade. While the company's 10-year median is 56.81 vs. the industry median of 15.71, Sartorius Stedim Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.71, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Interest Coverage of 3.21 is 79.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Interest Coverage is 3.21, which is 94% below median its own 10-year median of 56.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.93, compared to a current price of $20.09 — trading 16% below its estimated fair value. The current Interest Coverage is 3.21, which is 94% below median its 10-year median of 56.81 and 79.6% below the Medical Devices & Instruments industry median of 15.71. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Interest Coverage is 3.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $20.09 is trading 16% below its estimated GF Value™ of $23.93.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
Interest Coverage: 3.21 (94% below median its 10-year median of 56.81)
GF Value™: $23.93 vs. price of $20.09 (16% below fair value)
Industry Position: 79.6% below the Medical Devices & Instruments median (#369 of 468)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
